Soleno Therapeutics with ticker code (SLNO) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 9 and 8 with the average target price sitting at 8.67. With the stocks previous close at 1.95 this now indicates there is a potential upside of 344.6%. There is a 50 day moving average of 1.94 while the 200 day moving average is 1.95. The market capitalisation for the company is $154m. Visit the company website at: http://soleno.life
Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia and changed its name to Soleno Therapeutics in May 2017. Soleno Therapeutics was incorporated in 1999 and is headquartered in Redwood City, California.